Paper: Daratumumab Plus Lenalidomide (D-R) Versus Lenalidomide (R) Alone As Maintenance Therapy in Newly Diagnosed Multiple Myeloma (NDMM) after Transplant: Analysis of the Phase 3 Auriga Study Among Clinically Relevant Subgroups
Program: Oral and Poster Abstracts Type: Oral Session: 654. Multiple Myeloma: Pharmacologic Therapies: Optimizing Therapy in Newly Diagnosed Myeloma and Beyond Hematology Disease Topics & Pathways: Research, Clinical trials, Adult, Clinical Research, Plasma Cell Disorders, Diseases, Treatment Considerations, Biological therapies, Lymphoid Malignancies, Monoclonal Antibody Therapy, Study Population, Human, Measurable Residual Disease 1 Division of Hematology Oncology, University of Virginia, Charlottesville,
